Abstract: A series of glycosyl-substituted 1,3,4-oxadiazoles were synthesized by cyclization of glycosyl-acylthiosemicarbazides via a base-catalyzed reaction. The starting glycosyl-acylthiosemicarbazide derivatives were obtained by the reaction of glycosyl isothiocyanate with various hydrazides. The acetylcholinesterase (AChE) inhibitory activities of the products were tested by Ellman's method. The most active compounds were subsequently evaluated for the 50% inhibitory concentration (IC 50 ) values. N-(1,-3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole-2-amine (6i) possesses the best AChE -inhibition activity with an IC 50 of 1.61 ± 0.34 μm.
Introduction
Carbohydrates have long interested chemists and biochemists as a large natural resource [1] [2] [3] [4] . As an energy source and an element of many metabolic processes, sugars are present in every part of the human body [5] .
D-glucosamine is a naturally occurring amino sugar [6, 7] , one of the most abundant monosaccharides, and has been widely used in the prevention and/or treatment of rheumatoid arthritis and osteoarthritis [8, 9] . Furthermore, D-glucosamine exhibits a broad variety of bioactivities such as anti-inflammatory [10] , anti-cancer [11] and antibacterial [12] properties and it suppresses tumor growth [13] . Modified carbohydrates provide access to potential mimetics of naturally occurring amino sugars and represent targets for the development of anti-oxidant [14] , antiacetylcholinesterase (AChE) [15] , anti-proliferative [16] and other active agents [17] [18] [19] [20] .
The emergence of heterocyclic compounds with novel structures may promote discovery of new drugs and treatment of stubborn diseases [21] [22] [23] [24] . Recently, the oxadiazole chemistry has been developed extensively. 1,3,4-Oxadiazoles structurally resemble amides and esters [25] , and some compounds show similar pharmacokinetic properties [26] [27] [28] [29] [30] [31] . Moreover, recent studies have shown that a number of compounds containing the 1,3,4-oxadiazole skeleton act as monoamine oxidase inhibitors for the treatment of Alzheimer's disease (AD) [32] [33] [34] . AD is a chronic, neurodegenerative disorder that causes an irreversible dementia in elderly people [35] .
Researchers have been interested in molecular hybridbased approaches to find new compounds of potential biological activities [36, 37] . Based on the aforementioned information, herein we report the design and synthesis of novel D-glucosamine/1,3,4-oxadiazole hybrids with the oxadiazole ring offering an important pharmacophore to discover new potent AChE inhibitors. The synthesized derivatives were evaluated by Ellman's method for AChE inhibitors and to explore the influence of D-glucosamine against AChE inhibition.
Results and discussion

Chemistry
In the development of C2-glycosyl oxadiazoles, glycosyl isothiocyanate 3 was the critical intermediate compound.
Our strategy began with an attempted synthesis of this starting material without protection of hydroxyl groups at D-glucosamine hydrochloride but, to our disappointment, this attempt failed. The benzyl group was used to protect the hydroxyl groups. 1,3,4,6-Tetra-O-benzyl-β-D-glucosamine hydrochloride 1 was synthesized according to the literature [38, 39] . Treatment of compounds 1 with triethylamine in acetonitrile was followed by the addition of carbon disulfide, which furnished dithiocarbamic acid salt 2. Subsequent reaction of 2 with tosyl chloride (p-TsCl) yielded the key glycosyl isothiocyanate immediate 3 (Scheme 1). Compound 3 was treated with various hydrazides 4 to yield the glycosyl acylthiosemicarbazide derivatives 5a-j. Cyclization of the intermediate products 5 in a base-catalyzed reaction afforded the glycosyl oxadiazole derivatives 6a-j in high yields (Scheme 2).
Biological activity
The AChE-inhibition activities of the compounds were evaluated in vitro by Ellman's method [40] 
Conclusion
A new series of C2-glycosyl oxadiazole derivatives were designed, synthesized and subjected to biological evaluation. These compounds were characterized by NMR, IR and HRMS. Most of the compounds are active against AChE. Compound 6i shows the best AChE-inhibition activity with an IC 50 of 1.61 ± 0.34 μm.
Experimental Chemistry
All chemicals were purchased from commercial sources and used without further purification. Melting points were determined on a Yanaco melting point apparatus and were uncorrected. IR spectra were recorded on a Bruker Tensor 27 spectrometer in KBr pellets. 1 H NMR spectra were recorded on a Bruker Avance 400 MHz at ambient temperature using dimethyl sulfoxide-d 6 (DMSO-d 6 ) as a solvent and tetramethylsilane (TMS) as an internal standard. HRMS (ESI) analysis was performed on an Agilent 6230 mass spectrometer. Flash column chromatography was performed on silica 200-300 mesh. Amino-1,3,4,6-tetra-O-benzyl-2-deoxy-β-Dglucopyranose hydrochloride (1) A solution of D-glucosamine hydrochloride (10 g, 46.4 mmol) in water (70 mL) at room temperature was stirred and treated with NaOH (1.86 g, 46.5 mmol), and 15 min later dropwise with p-methoxybenzaldehyde (5.7 mL, 46.6 mmol). The mixture was stirred at ambient temperature for an additional 24 h, after which time the resulting white solid was filtered and washed with 500 mL of water to afford 2-(4-methoxy benzylidene)-2-deoxy-β-Dglucopyranose (11.4 g, 83%) . A mixture of this product and BnBr (14 mL, 118 mmol) in dimethylformamide (DMF) (50 mL) at 0°C was treated portion-wise with NaH (60%, 5 g, 125 mmol). The mixture was stirred at room temperature for 12 h, then diluted with a large amount of water and extracted with CH 2 Cl 2 (3 × 50 mL). The extract was concentrated under reduced pressure to give a yellow viscous liquid. The solution of the yellow liquid in acetone (100 mL) was treated with hydrochloric acid (7 mL, 5 N) to afford a white solid of 1 after reflux for 1 h. Product 1 was washed with acetone; yield 7.9 g (62%).
2-
2-Isothiocyanato-1,3,4,6-tetra-O-benzyl-2-deoxy-β-Dglucopyranose (3)
A solution of 1,3,4,6-tetra-O-benzyl-β-D-glucosamine hydrochloride 1 (1 mmol) and triethylamine (3 mmol) in acetonitrile (15 mL) was cooled in an ice bath and treated dropwise with carbon disulfide (1 mmol). The mixture was stirred for 2 h, then treated with p-TsCl 
General procedure for the preparation of N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-5-aryl-1,3,4-oxadiazole-2-amines 6a-j
Glycosyl isothiocyanate 3 (0.58 g, 1 mmol) was added in one portion to a stirred solution of hydrazide 4 (1 mmol) in MeCN (10 mL). The reaction mixture was heated under reflux for 3-4 h, and then the solvent was eliminated under reduced pressure. The residue was crystallized from aqueous ethanol to obtain the desired product 5a-j. p-TsCl (0.21 g, 1.1 mmol) was added to a stirred solution of acylthiosemicarbazide 5 (1 mmol) and triethylamine (0.16 mL, 2.0 mmol) in MeCN (10 mL). The mixture was stirred for about 2-3 h at 81°C, and the reaction progress was monitored by thinlayer chromatography (TLC). The desired compound 6a-j was purified by column chromatography on silica gel eluting with ethyl acetate/petroleum ether (1:2) to give a white amorphous product. N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-5-phenyl-1,3,4- N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-5-(2-chlorophenyl)-1,3 N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-5-(4-hydroxylphenyl)-1,3 N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-5-(4-iodinylphenyl)-1,3,4-oxadiazole-2-amine (6h The 50% inhibitory concentration (IC 50 ) was calculated from a doseresponse curve obtained by plotting the percentage of inhibition versus the log concentration with the use of the Origin 8.0 software. The results were described as mean ± standard deviation (SD).
